Example: Heart Attack

Search clinical trials for: Cytarabine

Total 1580 results

NCT06050941

Not yet recruiting

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults With Acute Myeloid Leukaemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes
NCT06034470

Not yet recruiting

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Acute Myeloid Leukemia | Myeloid Neoplasm
NCT06007911

Not yet recruiting

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed Adult AML | Refractory AML
NCT06001788

Not yet recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Neoplasms by Histologic Type | Acute Myeloid Leukemia | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | AML | Acute Leukemia | Hematologic Malignancy | NPM1 Mutation | AML With Mutated NPM1
NCT05992597

Recruiting

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
NCT05987696

Not yet recruiting

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Minimal Residual Disease | AML, Adult
NCT05982756

Recruiting

Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML

Acute Myeloid Leukemia | Bortezomib
NCT05966233

Not yet recruiting

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma (FIL_POLARDHAP)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory
NCT05959720

Recruiting

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil (BRALLA)

Acute Lymphoid Leukemia | Chemotherapeutic Toxicity | Minimal Residual Disease | Gene Abnormality
NCT05955261

Recruiting

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia
NCT05949762

Recruiting

Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly

Acute Myeloid Leukemia
NCT05941585

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Acute Myeloid Leukemia
NCT05939180

Recruiting

VA vs DA for ND Hig-risk AML

Acute Myeloid Leukemia
NCT05931263

Recruiting

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

Newly Diagnosed Peripheral T-cell Lymphoma
NCT05922384

Recruiting

Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma

HIV Infections | Lymphoma
NCT05921318

Recruiting

Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT

Hematologic Malignancy | Stem Cell Transplant Complications
NCT05918198

Recruiting

Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia
NCT05906914

Recruiting

Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia (CHA)

Acute Myeloid Leukemia, Adult
NCT05907486

Not yet recruiting

The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation

Thrombotic Disorder
NCT05904106

Not yet recruiting

Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML (VINCENT)

Acute Myeloid Leukemia
NCT05893472

Recruiting

A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.

Acute Myeloid Leukemia | Venetoclax
NCT05893329

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Acute Myeloid Leukemia
NCT05886049

Not yet recruiting

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation
NCT05876832

Not yet recruiting

A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Acute Myeloid Leukemia With FLT3/ITD Mutation
NCT05870995

Recruiting

Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia

Refractory Leukemia
NCT05863832

Recruiting

Study to Assess the Safety & Efficacy of Oral Ciprodiazole Versus Currently Used Ciprofloxacin & Metronidazole (CIPRO-001)

Surgical Site Infections
NCT05863845

Not yet recruiting

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

Diffuse Large B Cell Lymphoma
NCT05849662

Not yet recruiting

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Neurofibromatosis 1 | JMML | Leukemia, Juvenile Myelomonocytic | JCML | CBL Syndrome
NCT05829434

Not yet recruiting

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS (MAGROLIC)

Acute Myeloid Leukemia | Myelodysplastic Neoplasm
NCT05827549

Not yet recruiting

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia (ReCALL)

Acute Lymphoid Leukemia
NCT05814718

Not yet recruiting

Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT

Conditioning | Autologous Stem Cell Transplantation
NCT05814731

Not yet recruiting

Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

Conditioning | Haploidentical Stem Cell Transplantation
NCT05813132

Recruiting

BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

Lymphoma
NCT05807932

Recruiting

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia
NCT05807347

Recruiting

Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia

Refractory/Relapse Acute Myeloid Leukemia
NCT05807659

Recruiting

Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies

Myeloid Malignancies
NCT05805098

Recruiting

Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML (VHA)

Acute Myeloid Leukemia
NCT05805072

Not yet recruiting

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Relapsed/Refractory AML
NCT05801835

Recruiting

A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

Acute Myeloid Leukemia
NCT05780879

Not yet recruiting

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia
NCT05766514

Not yet recruiting

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Acute Myeloid Leukemia | Myelodysplastic Syndromes
NCT05761171

Not yet recruiting

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage
NCT05751044

Not yet recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
NCT05749276

Not yet recruiting

Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM) (DARALAM)

Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
NCT05745714

Not yet recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
NCT05740449

Not yet recruiting

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
NCT05739630

Recruiting

M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia

Acute Leukemia
NCT05735184

Recruiting

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML

Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Myeloid Sarcoma | Acute Myeloid Leukemia Recurrent | Mixed Phenotype Acute Leukemia | Mixed Lineage Acute Leukemia | Refractory AML | NPM1 Mutation | Mixed Lineage Leukemia Gene Mutation | AML With Mutated NPM1
NCT05726110

Recruiting

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia
NCT05712278

Recruiting

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukaemia

Search clinical trials for: Cytarabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations